Berna Rhein

Berna Rhein B.V. is a biotechnology company specializing in the development and manufacture of vaccines, currently operating as a subsidiary of Johnson & Johnson. The entity was established through the strategic merger of Berna Biotech and Rhein Biotech, combining Swiss and Dutch-German expertise in vaccine technology and recombinant protein production. Its historical portfolio includes well-known products such as Hepavax-Gene for Hepatitis B, Inflexal V for influenza, and Vivotif for typhoid fever. Following its acquisition by Crucell in 2006 and subsequently by Johnson & Johnson in 2011, the company's assets and technologies have been integrated into Janssen's global vaccine division. Berna Rhein remains a key legal and operational component of J&J's infectious disease and vaccine infrastructure in Europe. The company is recognized for its pioneering work in virosome-adjuvanted vaccines and yeast-based recombinant expression systems.